On Thursday, a federal advisory panel voted 8 to 6, with one abstention, to recommend that two research peptides, BPC-157 and KPV, be added to the list of substances that compounding pharmacies are allowed to mix into custom prescriptions. The same 8-6 margin carried both. The vote went against the recommendation of the FDA's own career scientists, who had told the panel that neither peptide had the safety or efficacy data to qualify.
The panel is the FDA's Pharmacy Compounding Advisory Committee, or PCAC. Its job is to advise the agency on which bulk ingredients belong on the Section 503A Bulks List, the roster of substances a pharmacist can compound without an FDA-approved drug behind them. Getting onto that list is the difference between a peptide sold in a legal gray zone and one a licensed pharmacy can prepare on a doctor's script. The Guardian reported the outcome ↗ Thursday evening.
In plain terms, both molecules are short chains of amino acids, the same class of thing as insulin or the GLP-1 weight-loss drugs, but far smaller and far less studied. BPC-157, sold for years in the fitness and longevity world as a healing compound, is a 15-amino-acid fragment that the committee discussed for ulcerative colitis. KPV is a three-amino-acid piece (lysine-proline-valine) used for inflammatory and wound conditions. Neither has an FDA-approved product behind it. The strongest human data for BPC-157, as we wrote in June ↗, is a single twelve-patient case series.
The FDA staff position was blunt. In the agency's own briefing documents ↗, career reviewers recommended against all seven peptides on this week's agenda, and at the meeting they said the studies they could find for KPV were not conducted in humans at all. Two FDA staffers, Russell Wesdyk and Mai Tu, told the committee that BPC-157 was not well characterized, meaning the agency could not be sure what molecule a compounder would actually be making.
The advisers went the other way, narrowly. Dr. Elizabeth Rebello of the University of Texas MD Anderson Cancer Center voted no and said the panel was "responding to a market-induced demand rather than a decision based in solid science." On the yes side, the argument was harm reduction: several members said a no vote would not end demand, it would only push patients toward unregulated sellers. That framing came through in public comment from Hims & Hers, whose chief medical officer testified that keeping peptides off the list drives them into the gray market. Hims shares rose 10 to 13 percent intraday on the news.
The vote sits inside a larger push. Health Secretary Robert F. Kennedy Jr. has publicly backed loosening restrictions on peptides, and Thursday was the first time the compounding committee has recommended adding these particular research peptides to the pathway. We flagged this meeting a month ago ↗, when the seven-peptide agenda was set. NPR reported that the advisers voted to ease regulation ↗ of the compounds, and Time framed it as a committee siding with peptides ↗ over its own agency's objection.
Two cautions the coverage mostly buried. First, the vote is a recommendation, not a rule. The 503A list changes only when the FDA formally acts, and the agency is not bound by its committee. Second, the panel was not finished. TB-500 and MOTS-c were also on Thursday's agenda, and a second day of votes on DSIP, Semax, and Epitalon was set for Friday, so the count of peptides in play is still moving.
What it changes for anyone working on peptides: BPC-157 and KPV are about to become easier to obtain through a legal channel, without the human trials that any approved drug has to clear. On peptidemodel, BPC-157 ↗ sits against tissue repair ↗ and KPV ↗ against MC1R ↗, both tagged as research peptides precisely because the clinical evidence is thin. A compounding pathway does not change the evidence. It changes who is allowed to sell it.